The FDA warned prescribers about the risk of serious liver injury associated with the use of the anti-thyroid drug propylthiouracil (PTU).
FDA’s warning highlights:
- There is an increased risk of liver injury with propylthiouracil (PTU) when compared to methimazole.
- Monitor for symptoms and signs of liver injury when propylthiouracil is chosen as anti-thyroid therapy. This should be emphasized during the first six months after initiating therapy.
Read the news release